Biological response modifiers are a class of drugs used to treat rheumatoid arthritis (RA). Your doctor may suggest that you start right after your diagnosis, which can help address joint damage.

The global rheumatoid arthritis drugs market was valued at $57,929 million in 2019, and is projected to reach $62,935 million by 2027, registering a CAGR of 2.8% from 2020 to 2027. Alarming rise in ...

Monoclonal antibodies are novel therapeutic agents used with great success in the treatment of rheumatoid arthritis (RA). Different parts of the immune system have been targeted by monoclonal ...

Rheumatoid arthritis (RA) is a form of arthritis and an autoimmune ... Self-care measures like rest and anti-inflammatory medicines may be able to help with flares—but when they don't, it's time to ...

AZD-1163 is under clinical development by AstraZeneca and currently in Phase I for Rheumatoid Arthritis. According to GlobalData, Phase I drugs for Rheumatoid Arthritis have a 69% phase transition ...

Rheumatoid arthritis (RA) is an autoimmune disease that causes swelling, pain, and stiffness in the joints. Scientists from ...

The Alzheimer’s epidemic continues to cast a shadow over the lives of millions. This disease erodes memories and cognitive ...

Ivarmacitinib, a novel Janus kinase 1 inhibitor, may be considered a potential treatment for patients with moderate to severe ...

The management of rheumatoid arthritis has seen tremendous changes over the past 25 years, since the increasing availability of biological disease-modifying antirheumatic drugs (DMARDs) with various ...